NASDAQ:CRBP - Corbus Pharmaceuticals Stock Price, Forecast & News

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CRBP stock has increased by 26.2% and is now trading at $5.20. View which stocks have been mosted impacted by Coronavirus.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Corbus Pharmaceuticals.

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Corbus Pharmaceuticals.

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) issued its quarterly earnings data on Thursday, March, 12th. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.05. The biopharmaceutical company had revenue of $2.57 million for the quarter, compared to analysts' expectations of $4.64 million. Corbus Pharmaceuticals had a negative net margin of 197.69% and a negative return on equity of 227.79%. View Corbus Pharmaceuticals' earnings history.

4 brokerages have issued 1 year target prices for Corbus Pharmaceuticals' stock. Their forecasts range from $18.00 to $112.00. On average, they anticipate Corbus Pharmaceuticals' share price to reach $44.25 in the next twelve months. This suggests a possible upside of 751.0% from the stock's current price. View analysts' price targets for Corbus Pharmaceuticals.

News coverage about CRBP stock has been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Corbus Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutCorbus Pharmaceuticals.

Some companies that are related to Corbus Pharmaceuticals include Insmed (INSM), Arvinas (ARVN), SAGE Therapeutics (SAGE), Zymeworks (ZYME), BELLUS Health (BLUSF), Pacira Biosciences (PCRX), Constellation Pharmaceuticals (CNST), Corcept Therapeutics (CORT), Akcea Therapeutics (AKCA), Theravance Biopharma (TBPH), Dicerna Pharmaceuticals (DRNA), Karyopharm Therapeutics (KPTI), ZEALAND PHARMA/S (ZEAL), CytoDyn (CYDY) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Exelixis (EXEL), Viveve Medical (VIVE), Canopy Growth (CGC), Western Digital (WDC), Cronos Group (CRON) and Zynerba Pharmaceuticals (ZYNE).

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CRBP stock can currently be purchased for approximately $5.20.

Corbus Pharmaceuticals has a market capitalization of $376.95 million and generates $36.14 million in revenue each year. The biopharmaceutical company earns $-71,450,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis. Corbus Pharmaceuticals employs 77 workers across the globe. View additional information about Corbus Pharmaceuticals.

The official website for Corbus Pharmaceuticals is http://www.corbuspharma.com/.

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]